{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-246973","form_type":"8-K","ticker":"AMRN","cik":"0000897448","company_name":"AMARIN CORP PLCUK","filed_at":"2025-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.537640+00:00","generated_at":"2026-05-17T02:55:07.084950+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Amarin promotes David Keenan to EVP, COO effective October 17, 2025","bullets":["David Keenan, previously EVP Technical Operations and President of Europe, appointed COO effective Oct 17, 2025.","Dr. Keenan joined Amarin in May 2022 as SVP Technical Operations; promoted to EVP in July 2023.","No change to compensation as a result of the COO appointment; no family relationships or arrangements.","Keenan brings over 30 years leadership in biopharma; holds PhD in Organic Chemistry and MBA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-246973","json":"https://secwatch.observer/filing/0001193125-25-246973.json","markdown":"https://secwatch.observer/filing/0001193125-25-246973.md","text":"https://secwatch.observer/filing/0001193125-25-246973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/897448/000119312525246973/0001193125-25-246973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/897448/000119312525246973/amrn-20251017.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:55:07.084950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}